Stereotaxis (NYSEAMERICAN:STXS) Announces Quarterly Earnings Results

Stereotaxis (NYSEAMERICAN:STXS) issued its quarterly earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05), FiscalAI reports. The business had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $8.35 million. Stereotaxis had a negative net margin of 69.50% and a negative return on equity of 163.30%.

Here are the key takeaways from Stereotaxis’ conference call:

• Recurring revenue reached $6.2 million in Q2, driven by the launch of MAGiC and a 270% sequential increase in robotic catheter revenue. Management expects recurring revenue to rise to approximately $7 million in Q3 and $8 million in Q4.
• MAGiC adoption is expanding, with roughly a dozen U.S. hospitals approved to purchase the catheter and procedure-level disposable revenue generally in the $5,000–$8,000-plus range. Demand currently exceeds supply, but the company expects about $1 million of incremental catheter revenue in each of the next two quarters as manufacturing ramps.
• Stereotaxis received its first U.S. GenesisX order and expects installation this fall alongside a non-modified X-ray, supporting formal compatibility with that manufacturer. Synchrony also generated initial orders and is expected to contribute more than $1 million of system revenue per quarter in the near term.
• Q2 revenue was $7.7 million, down year over year because no robotic system was delivered, while the company posted a $4.5 million net loss and $3.7 million of negative free cash flow. Gross margins remained pressured by low manufacturing volumes, and management acknowledged ongoing adoption barriers including catheter supply, GenesisX validation, and X-ray compatibility.
• Management reiterated its expectation of reaching cash-flow profitability in the first half of 2027 without additional financing, assuming continued catheter adoption and modest system sales. The company also highlighted longer-term growth opportunities from a wireless/mobile robot, pulse-field-ablation catheters, AI-enabled surgery, and the recently completed Robocath acquisition.

Stereotaxis Stock Performance

Shares of NYSEAMERICAN STXS traded down $0.06 during mid-day trading on Wednesday, hitting $1.40. The stock had a trading volume of 1,372,561 shares, compared to its average volume of 608,693. The business has a 50 day moving average price of $1.63 and a two-hundred day moving average price of $1.87. Stereotaxis has a 1 year low of $1.24 and a 1 year high of $3.59. The firm has a market cap of $137.10 million, a P/E ratio of -5.83 and a beta of 1.37.

Institutional Investors Weigh In On Stereotaxis

Large investors have recently added to or reduced their stakes in the company. WealthPLAN Partners LLC bought a new position in shares of Stereotaxis during the fourth quarter valued at about $29,000. BNP Paribas Financial Markets increased its holdings in Stereotaxis by 106.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock valued at $36,000 after purchasing an additional 5,910 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in Stereotaxis during the 3rd quarter valued at approximately $38,000. HRT Financial LP purchased a new stake in Stereotaxis in the 4th quarter worth approximately $42,000. Finally, Moneta Group Investment Advisors LLC bought a new stake in shares of Stereotaxis in the 3rd quarter worth approximately $43,000. Institutional investors own 45.35% of the company’s stock.

Trending Headlines about Stereotaxis

Here are the key news stories impacting Stereotaxis this week:

• Positive Sentiment: TD Cowen maintained a Buy rating while lowering its price target from $5.00 to $3.00. The revised target still implies substantial upside from recent trading levels, signaling that the analyst views the selloff as potentially excessive. Benzinga analyst price-target report
• Positive Sentiment: Management expects recurring revenue to reach approximately $8 million in the fourth quarter of 2026. The outlook suggests growing adoption of the company’s MAGiC system, although demand is currently limited by supply constraints. Seeking Alpha recurring-revenue report
• Neutral Sentiment: Stereotaxis reported second-quarter revenue of $7.67 million and an adjusted loss of $0.05 per share. The EPS result matched the consensus estimate cited by MarketBeat, but the company’s broader business update points to a still-developing growth and commercialization story. Stereotaxis second-quarter results
• Negative Sentiment: Revenue fell short of the approximately $8.35 million analyst estimate, while Zacks said the $0.05-per-share loss was worse than its $0.03 expected loss. Stereotaxis also reported a negative net margin of 69.5% and negative return on equity, reinforcing concerns about profitability and execution. Zacks Stereotaxis earnings report

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. TD Cowen cut their price objective on shares of Stereotaxis from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Wednesday. Citigroup reiterated a “market outperform” rating on shares of Stereotaxis in a research report on Wednesday, June 3rd. Finally, Piper Sandler reissued an “overweight” rating and issued a $3.50 price target (down from $4.00) on shares of Stereotaxis in a research note on Wednesday, May 13th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $3.70.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.